Evidence map›Paper›PMID 41563221›Full record

ArticleJACC. Case reports2026

Heart Transplantation and Cancer Risk in a BRCA1 Breast Cancer Survivor.

Laura Noteware, Eleanor Keller, Dor Lotan, Ersilia M DeFilippis, Carolyn Hennecken, Afsana Rahman, Kevin Clerkin, Sun Hi Lee, Adil Yunis, Edward Lin and 9 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Laura NotewareDepartment of Medicine, Columbia University, New York, New York, USA.
Eleanor KellerDepartment of Medicine, Columbia University, New York, New York, USA.
Dor LotanDepartment of Cardiology, Columbia University, New York, New York, USA.
Ersilia M DeFilippisDepartment of Cardiology, Columbia University, New York, New York, USA.
Carolyn HenneckenDepartment of Cardiology, Columbia University, New York, New York, USA.
Afsana RahmanDepartment of Cardiology, Columbia University, New York, New York, USA.
Kevin ClerkinDepartment of Cardiology, Columbia University, New York, New York, USA.
Sun Hi LeeDepartment of Cardiology, Columbia University, New York, New York, USA.
Adil YunisDepartment of Cardiology, Columbia University, New York, New York, USA.
Edward LinDepartment of Cardiology, Columbia University, New York, New York, USA.
David BaeDepartment of Cardiology, Columbia University, New York, New York, USA.
Kyung Taek OhDepartment of Cardiology, Columbia University, New York, New York, USA.
Paolo ColomboDepartment of Cardiology, Columbia University, New York, New York, USA.
Melana YuzefpolskayaDepartment of Cardiology, Columbia University, New York, New York, USA.
Farhana LatifDepartment of Cardiology, Columbia University, New York, New York, USA.
Gabriel SayerDepartment of Cardiology, Columbia University, New York, New York, USA.
Nir UrielDepartment of Cardiology, Columbia University, New York, New York, USA.
Mariam El-AshmawyDepartment of Oncology, Columbia University, New York, New York, USA.
Jayant RaikhelkarDepartment of Cardiology, Columbia University, New York, New York, USA. Electronic address: jkr2146@cumc.columbia.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBRCA1 carriers face increased risk of cancer. Limited data exist for post-transplant immunosuppression and malignancy screening in this population. CASE SUMMARY: A 67-year-old woman with BRCA1-positive breast cancer developed anthracycline-induced cardiomyopathy requiring heart transplantation. She received enhanced surveillance for secondary malignancies with an uncomplicated course over 13 years. However, despite reduction in immunosuppression, 14 years later she developed a rare, fatal, metastatic adnexal tumor, eccrine porocarcinoma. WHY BEYOND THE GUIDELINES?: There are no established guidelines for post-transplant immunosuppression or cancer surveillance in patients with hereditary cancer syndromes such as BRCA1-associated hereditary breast cancer. DISCUSSION: This case demonstrates the complexity of balancing immunosuppression and management in patients with germline mutations who require heart transplantation. Further work is required to understand the intersection of oncologic genetic risk with immunosuppression and develop best practices for screening this distinct population. TAKE-HOME MESSAGES: Cancer survivorship in BRCA1 carriers adds complexity to post-transplant management. Multidisciplinary, personalized care is essential for optimizing outcomes in such high-risk patients.

Indexed as

cancercardiac transplantationcardio-oncologygenetic disorders

Identifiers

PMID41563221
PMCPMC12948563

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.